Why Aclarion Shares Are Soaring Today

Aclarion Inc ACON shares are trading higher after the company published durability data for its back pain treatment. 

What Happened: Aclarion published two-year data demonstrating improved surgical outcomes for discogenic low back pain surgeries. 

A trial of 78 patients showed a 22% improvement in those using Nociscan, an augmented intelligence platform used to measure pain biomarkers in the lumbar spine.

Orthopedic surgeon Matthew Gornet said, "I believe Nociscan is something that will accurately help all physicians treating chronic low back pain, and I believe it can change the standard of care. I feel uncomfortable now moving forward in treatment of low back pain patients without the information Nociscan provides."

Aclarion said a healthcare economics study illustrating dominant economic and clinical benefits for Nociscan has been submitted for presentation at upcoming spine society meetings. The company plans to move forward with additional clinical trials. 

Aclarion is a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

Photo: US Stocks To Open lower As Tech Earnings Loom: Why This Analyst Sees Equity Market Struggling In 'Weeks, Months Ahead'

ACON Price Action: Aclarion shares were up 71.6% at $1.27 at time of publication, according to Benzinga Pro.

This illustration was generated using artificial intelligence via MidJourney.